Sugi Predict

Sugi Predict / Compounds / SCHEMBL5434684

SCHEMBL5434684

SCHEMBL5434684

NC(N)=NC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 5/20 0.65
▸ SRD5A2 P31213 4/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ PARP15 Q460N3 3/20 0.52
▸ PARP14 Q460N5 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ PARP16 Q8N5Y8 1/20 0.52
▸ PARP11 Q9NR21 1/20 0.52
▸ PARP4 Q9UKK3 1/20 0.52
▸ BACE1 P56817 2/20 0.50
▸ SLC9A1 P19634 1/20 0.49
▸ TPH1 P17752 1/20 0.49
▸ TNKS O95271 1/20 0.49
▸ TNKS2 Q9H2K2 1/20 0.49
▸ PARP2 Q9UGN5 1/20 0.49
▸ HTR7 P34969 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ ERCC5 P28715 1/20 0.47
▸ FEN1 P39748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7827863 0.83 AKR1C3 (0.60) PARP10PARP15PARP14SLC9A1TNKS
SCHEMBL828587 0.82 TPH1 (0.55) SLC9A1TPH1HTR7HTR2B
Hydrochloric Acid SCHEMBL27319279 0.81 TPH1 (0.53) SLC9A1TPH1HTR7HTR2B
Hydrochloric Acid SCHEMBL27296270 0.81 TPH1 (0.53) SLC9A1TPH1HTR7HTR2B
SCHEMBL27489015 0.81 TPH1 (0.53) SLC9A1TPH1HTR7HTR2B
SCHEMBL19402969 0.79 PARP10 (0.60) PARP10SRD5A2SMN1; SMN2PARP15PARP14
SCHEMBL5441718 0.79 SLC9A1 (0.53) SMN1; SMN2SLC9A1TPH1HTR7HTR2B
Terephthalamide SCHEMBL4205368 0.79 PARP10 (1.00) PARP10SRD5A2SMN1; SMN2PARP15PARP14
SCHEMBL606429 0.79 PARP10 (1.00) PARP10SRD5A2SMN1; SMN2PARP15PARP14
Hydrochloric Acid SCHEMBL7824640 0.78 SLC9A1 (0.51) SMN1; SMN2SLC9A1TPH1HTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
CN-101111475-B Antiviral compounds and methods BIOTRON LTD 2012-09-05 — — CN disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP disclosed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PARP10 1439/4885SRD5A2 3175/4885SMN1; SMN2 2555/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PARP10 1439/4885SRD5A2 3175/4885SMN1; SMN2 2555/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PARP10 1279/4885SRD5A2 2919/4885SMN1; SMN2 2257/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 PARP10 1439/4885SRD5A2 3175/4885SMN1; SMN2 2555/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 PARP10 1445/4885SRD5A2 3441/4885SMN1; SMN2 2399/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 PARP10 1445/4885SRD5A2 3441/4885SMN1; SMN2 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.